Uterine fibroid

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Tuesday, August 16, 2022 - 9:30pm

The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joiningMyovantin accordance with NYSEs Listed CompanyManual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 120,550 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care

Retrieved on: 
Friday, August 12, 2022 - 1:01pm

Hologic, Inc. is a global medical technology innovator primarily focused on improving womens health and well-being through early detection and treatment.

Key Points: 
  • Hologic, Inc. is a global medical technology innovator primarily focused on improving womens health and well-being through early detection and treatment.
  • The Black Promoters Collective (BPC) is a coalition of six of the nation's top independent concert promotion and event production companies.
  • As a 100% Black-owned business, its mission is to be the world's leading producer and provider of culturally relevant live entertainment experiences.
  • This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

US Fertility welcomes Amy Lee Harris, M.D., to the Shady Grove Fertility (SGF) physician team

Retrieved on: 
Wednesday, July 27, 2022 - 8:15pm

COLORADO SPRINGS, Colo.,  July 27, 2022 /PRNewswire-PRWeb/ -- US Fertility, the largest, physician-led, integrated network of top-tier fertility practices in the United States, welcomes Amy Lee Harris, M.D., to Shady Grove Fertility's (SGF) Colorado Springs, Colorado, location. Dr. Harris is now accepting new patient appointments.

Key Points: 
  • COLORADO SPRINGS, Colo., July 27, 2022 /PRNewswire-PRWeb/ -- US Fertility , the largest, physician-led, integrated network of top-tier fertility practices in the United States, welcomes Amy Lee Harris, M.D.
  • , to Shady Grove Fertility's (SGF) Colorado Springs, Colorado , location.
  • "I am honored to join the extraordinary SGF Colorado team that is dedicated to providing world-class fertility care," shares Dr. Harris.
  • Dr. Harris will provide comprehensive fertility services, including:
    fertility and ovarian reserve testing and diagnosis,

ObsEva Announces Corporate Updates

Retrieved on: 
Wednesday, July 27, 2022 - 12:00pm

53 LR of the SIX Swiss Exchange

Key Points: 
  • 53 LR of the SIX Swiss Exchange
    GENEVA, Switzerland July 27, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for womens health, today announced that it plans to initiate a corporate restructuring and refocus the Companys development and commercialization strategy.
  • The FDAs review of the NDA is still ongoing and ObsEva has not been informed of any final decision by the agency.
  • In addition, ObsEva will assess strategic options with respect to pipeline development and the worldwide rights it holds for nolasiban, excluding China.
  • Consistent with ObsEvas plans to restructure its operations, ObsEva will initiate a mass dismissal process, pursuant to Swiss law.

Embolx Files 510(k) for New Soldier® High Flow Microcatheter

Retrieved on: 
Thursday, July 21, 2022 - 3:00pm

SUNNYVALE, Calif., July 21, 2022 /PRNewswire/ -- Embolx, Inc. a medical device company developing microcatheters for arterial embolization procedures, today announced that the company has filed a 510(k) to the Food and Drug Administration (FDA) for its new product line of high flow microcatheters called "Soldier," that uses the same Ultra-Thin Wall (UTW) technology initially developed for its flagship product Sniper®. UTW technology allows microcatheters to be smaller in outer diameter yet maintain the largest internal lumens on the market. UTW in combination with unique design innovations enables Soldier to display best-in-class tracking, torquing, and flow rates. Currently available in the European market, Soldier's highly anticipated arrival in the United States market is expected to shift the paradigm and set a new standard for both high flow microcatheters and micro-microcatheters.

Key Points: 
  • UTW in combination with unique design innovations enables Soldier to display best-in-class tracking, torquing, and flow rates.
  • The Soldier microcatheter will be available in 2.0 Fr and 2.5 Fr and will come in three lengths 130 cm, 155 cm, and 165 cm.
  • The addition of the Soldier product line will expand the use of Embolx products for all types of embolization, immunotherapy, and drug delivery procedures.
  • Embolx is committed to dramatically improving the treatment of various conditions, including cancerous tumors, benign prostatic hyperplasia, and uterine fibroids.

Inaugural Fibroids Awareness Day aims to break the silence and isolation around misunderstood disease that will impact 70% of all women by age 50

Retrieved on: 
Thursday, July 21, 2022 - 12:01pm

It gave me hope and a support system where I had access to all these women with the same lived experience.

Key Points: 
  • It gave me hope and a support system where I had access to all these women with the same lived experience.
  • Thirty to 50% of women are carriers of fibroids, with symptoms that vary from woman to woman.
  • In honour of Fibroids Awareness Day, Canadians are encouraged to share their stories using the hashtag #FightingFibroids and #Vivre100Fibromes.
  • Founded in 2016, Vivre 100 Fibromes is a nonprofit organization whose mission is to improve the care of women with uterine fibroids.

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

Retrieved on: 
Monday, July 18, 2022 - 9:30pm

The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule303A.08.

Key Points: 
  • The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule303A.08.
  • The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 175,600 common shares ofMyovant.
  • The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements.
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.

Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow

Retrieved on: 
Thursday, July 14, 2022 - 9:30pm

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Key Points: 
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
  • Profound is also commercializing Sonalleve, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022

Retrieved on: 
Wednesday, July 13, 2022 - 11:45am

BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.

Key Points: 
  • BASEL, Switzerland, July 13, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE:MYOV), today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter, ended June 30, 2022.
  • The webcast and conference call will be held at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on July 27, 2022.
  • The live webcast can also be accessed by visiting the companys investor relations page of Myovants website at: https://investors.myovant.com/ .
  • Myovant Sciencesaspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy.